40:I[185,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SendEmailButton"] 42:I[63625,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"AddToLibraryButton"] 43:I[29721,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ShareButton"] 44:I[58016,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ProcessEpisodeButton"] 45:I[45269,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SignupCTA"] 3a:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2026-07-25T19:41:55.000Z","children":"July 25, 2026"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:01:07"}],false]}] 41:T47b,

Vidcast: https://www.instagram.com/p/DbOljwysK0r/

For decades, people living with chronic hepatitis B have faced the reality of lifelong medication to keep the virus under control. But this week brought encouraging news from researchers across the globe working collaboratively.

In a late-stage clinical trial, an experimental medication called bepirovirsen enabled about one in five patients to stop treatment while maintaining long-term suppression of the virus. Researchers describe this as a functional cure—meaning the virus remains under control without the need for continuous medication. While it isn't a cure for everyone, it's one of the most promising advances against hepatitis B in years.

If future studies confirm these results and regulators approve the treatment, millions of people worldwide could eventually have an alternative to lifelong therapy.

References for this report are available on my website.

#HepatitisB #MedicalResearch #ClinicalTrials #LiverHealth #HealthcareInnovation